BlackRock, Inc. Reduces Stake in Arrivent Biopharma Inc.

BlackRock, Inc. has filed a Schedule 13G/A amendment with the SEC, disclosing a significant reduction in its stake in Arrivent Biopharma Inc. As of September 30, 2025, BlackRock's ownership has decreased to 4.9% of the common stock, down from a previous higher percentage. The filing indicates that BlackRock now holds 2,007,338 shares, a decrease of 43,371,987 shares from its previous holding. The value of the shares held has also decreased by $50,361,816,424.92, reflecting a 95.5765% drop. The filing certifies that the shares were acquired and are held in the ordinary course of business and not for the purpose of influencing the control of the issuer.